In the past two pandemic years, Emergency Departments (ED) have been overrun with COVID-19-suspicious patients. Some data on the role played by laboratory biomarkers in the early risk stratification of COVID-19 patients have been recently published. The aim of this study is to assess the potential role of the new biomarker mid-regional proadrenomedullin (MR-proADM) in stratifying the in-hospital mortality risk of COVID-19 patients at the triage. A further goal of the present study is to evaluate whether MR-proADM together with other biochemical markers could play a key role in assessing the correct care level of these patients. Data from 321 consecutive patients admitted to the triage of the ED with a COVID-19 infection were analyzed. Epidemiological; demographic; clinical; laboratory; and outcome data were assessed. All the biomarkers analyzed showed an important role in predicting mortality. In particular, an increase of MR-proADM level at ED admission was independently associated with a threefold higher risk of IMV. MR-proADM showed greater ROC curves and AUC when compared to other laboratory biomarkers for the primary endpoint such as in-hospital mortality, except for CRP. This study shows that MR-proADM seems to be particularly effective for early predicting mortality and the need of ventilation in COVID-19 patients admitted to the ED.

Minieri, M., Di Lecce, V.n., Lia, M.s., Maurici, M., Leonardis, F., Longo, S., et al. (2022). Predictive Value of MR-proADM in the Risk Stratification and in the Adequate Care Setting of COVID-19 Patients Assessed at the Triage of the Emergency Department. DIAGNOSTICS, 12(8), 1-14 [10.3390/diagnostics12081971].

Predictive Value of MR-proADM in the Risk Stratification and in the Adequate Care Setting of COVID-19 Patients Assessed at the Triage of the Emergency Department

Minieri M.
;
Maurici M.;Leonardis F.;Longo S.;Terrinoni A.;Malagnino V.;Pieri M.;D'Agostini C.;Bernardini S.;Legramante J. M.
2022-01-01

Abstract

In the past two pandemic years, Emergency Departments (ED) have been overrun with COVID-19-suspicious patients. Some data on the role played by laboratory biomarkers in the early risk stratification of COVID-19 patients have been recently published. The aim of this study is to assess the potential role of the new biomarker mid-regional proadrenomedullin (MR-proADM) in stratifying the in-hospital mortality risk of COVID-19 patients at the triage. A further goal of the present study is to evaluate whether MR-proADM together with other biochemical markers could play a key role in assessing the correct care level of these patients. Data from 321 consecutive patients admitted to the triage of the ED with a COVID-19 infection were analyzed. Epidemiological; demographic; clinical; laboratory; and outcome data were assessed. All the biomarkers analyzed showed an important role in predicting mortality. In particular, an increase of MR-proADM level at ED admission was independently associated with a threefold higher risk of IMV. MR-proADM showed greater ROC curves and AUC when compared to other laboratory biomarkers for the primary endpoint such as in-hospital mortality, except for CRP. This study shows that MR-proADM seems to be particularly effective for early predicting mortality and the need of ventilation in COVID-19 patients admitted to the ED.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/12
English
COVID-19 biomarkers
emergency department
mid-regional proadrenomedullin
triage
Minieri, M., Di Lecce, V.n., Lia, M.s., Maurici, M., Leonardis, F., Longo, S., et al. (2022). Predictive Value of MR-proADM in the Risk Stratification and in the Adequate Care Setting of COVID-19 Patients Assessed at the Triage of the Emergency Department. DIAGNOSTICS, 12(8), 1-14 [10.3390/diagnostics12081971].
Minieri, M; Di Lecce, Vn; Lia, Ms; Maurici, M; Leonardis, F; Longo, S; Colangeli, L; Paganelli, C; Levantesi, S; Terrinoni, A; Malagnino, V; Brunetti, Dj; Giovannelli, A; Pieri, M; Ciotti, M; D'Agostini, C; Gabriele, M; Bernardini, S; Legramante, Jm
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Minieri_et_al_2022_Diagnostics.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 793.17 kB
Formato Adobe PDF
793.17 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/310436
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact